Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage have propelled their returns.
However, not all companies with momentum are long-term winners, and many investors have lost money by following short-term trends. On that note, here are three stocks that are likely overheated and some you should look into instead.
FormFactor (FORM)
One-Month Return: +44.4%
With customers across the foundry and fabless markets, FormFactor (NASDAQ:FORM) is a US-based provider of test and measurement technologies for semiconductors.
Why Are We Cautious About FORM?
- Muted 2.5% annual revenue growth over the last five years shows its demand lagged behind its semiconductor peers
- Gross margin of 39.8% reflects its high production costs
- Weak free cash flow margin of 5.9% has deteriorated further over the last five years as its investments increased
FormFactor’s stock price of $130.50 implies a valuation ratio of 69.2x forward P/E. To fully understand why you should be careful with FORM, check out our full research report (it’s free).
Corcept (CORT)
One-Month Return: +37.5%
Focusing on the powerful stress hormone that affects everything from metabolism to immune function, Corcept Therapeutics (NASDAQ:CORT) develops and markets medications that modulate cortisol to treat endocrine disorders, cancer, and neurological diseases.
Why Do We Think Twice About CORT?
- Incremental sales over the last five years were much less profitable as its earnings per share fell by 6.9% annually while its revenue grew
- Free cash flow margin dropped by 27.1 percentage points over the last five years, implying the company became more capital intensive as competition picked up
- Eroding returns on capital suggest its historical profit centers are aging
At $44.26 per share, Corcept trades at 116.2x forward P/E. If you’re considering CORT for your portfolio, see our FREE research report to learn more.
Affirm (AFRM)
One-Month Return: +26.7%
Founded by PayPal co-founder Max Levchin with a mission to create honest financial products, Affirm (NASDAQ:AFRM) provides a payment network that allows consumers to make purchases and pay for them over time with transparent, flexible installment loans.
Why Does AFRM Fall Short?
- Negative return on equity shows that some of its growth strategies have backfired
- High net-debt-to-EBITDA ratio of 7× could force the company to raise capital at unfavorable terms if market conditions deteriorate
Affirm is trading at $60.43 per share, or 15.4x forward P/E. Dive into our free research report to see why there are better opportunities than AFRM.
Stocks We Like More
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.